Therefore, we next compared the in vivo CD8+ T cell–mediated antitumor GVT effects of WT and SDHA-KO B6 CD8+ T cells in the context of B6 CD4+ T cell–mediated GVHD, by utilizing the above model. This evidence concerns the gene CD4 and graft versus host disease.